CD4-reactive antibodies in systemic lupus erythematosus

Area of Science:

• Immunology
• Autoimmunity
• Cell Biology

Background:

• Regulatory antibodies (Ab) interact with ligands on T and B lymphocytes.
• CD4 glycoprotein is a potential target for regulatory antibodies.
• Elevated CD4-reactive Ab are observed in HIV and Systemic Lupus Erythematosus (SLE) patients.

Purpose of the Study:

• To investigate the existence and characteristics of antibodies directly targeting CD4 in SLE patients.
• To compare anti-CD4 antibody levels in SLE patients with rheumatoid arthritis and healthy controls.

Main Methods:

• Serum samples from SLE patients, rheumatoid arthritis patients, and normal controls were assessed.
• Immunofluorescence was used to detect binding to native CD4.
• ELISA and Western blot were employed to analyze binding to recombinant CD4.
• Antibody isotypes (IgM, IgG) and light chain usage (kappa, lambda) were evaluated.

Main Results:

• A subset of SLE patients (17.2%) exhibited significantly increased serum concentrations of anti-CD4 antibodies.
• These antibodies demonstrated specific binding to both native and recombinant CD4.
• Anti-CD4 antibodies were of IgM and/or IgG isotypes.
• Binding was not significantly influenced by DNA/anti-DNA immune complexes.
• High CD4 reactivity was associated with active SLE disease (SLEDAI) and clinical features like neuropsychiatric disease and lymphopenia.

Conclusions:

• A distinct subset of SLE patients possesses autoantibodies directly targeting the CD4 molecule.
• The presence of anti-CD4 antibodies in SLE is linked to disease activity and specific clinical manifestations.
• Further research into the pathogenic role of anti-CD4 antibodies in SLE is warranted.